{"DataElement":{"publicId":"6421501","version":"1","preferredName":"Microscopic Examination Detail","preferredDefinition":"Detail of the microscopic examination used to obtain the measurement or finding.","longName":"MITSTDTL","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"6421083","version":"1","preferredName":"Microscopic Findings Domain Microscopic Findings Measurement, Test or Examination Detail","preferredDefinition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to microscopic findings._Particulars considered individually and in relation to a microscopic findings measurement, test or examination.","longName":"6407670v1.0:6421081v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"6407670","version":"1","preferredName":"Microscopic Findings Domain","preferredDefinition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to microscopic findings.","longName":"C95095","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Microscopic Findings Domain","conceptCode":"C95095","definition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to microscopic findings.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"73F3D377-A300-2627-E053-F662850A04B0","latestVersionIndicator":"Yes","beginDate":"2018-08-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-21","modifiedBy":"ONEDATA","dateModified":"2018-08-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6421081","version":"1","preferredName":"Microscopic Findings Measurement, Test or Examination Detail","preferredDefinition":"Particulars considered individually and in relation to a microscopic findings measurement, test or examination.","longName":"C117579","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Microscopic Findings Measurement, Test or Examination Detail","conceptCode":"C117579","definition":"Particulars considered individually and in relation to a microscopic findings measurement, test or examination.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"746EE4B0-22AA-43C2-E053-F662850AD055","latestVersionIndicator":"Yes","beginDate":"2018-08-27","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-08-27","modifiedBy":"ONEDATA","dateModified":"2018-08-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435019","version":"1","preferredName":"Conceptual Entity","preferredDefinition":"An organizational header for concepts representing mostly abstract entities.","longName":"C20181","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D8-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CDISC:Clinical Data Interchange Standards Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"746EE4B0-22BB-43C2-E053-F662850AD055","latestVersionIndicator":"Yes","beginDate":"2018-08-27","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-08-27","modifiedBy":"KUMMEROA","dateModified":"2021-06-09","changeDescription":"2021-6-9 ak Released per governance approval.; Created as part of the CDISC mapping task_ghd_08.27.18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6678061","version":"1","preferredName":"CDISC SDTM Microscopic Findings Test Detail Terminology Type","preferredDefinition":"Terminology associated with the microscopic findings test detail codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM)._Something distinguishable as an identifiable class based on common qualities.","longName":"MIFTSDTL","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"TUMOR PROPORTION SCORE","valueDescription":"Tumor Proportion Score","ValueMeaning":{"publicId":"6678073","version":"1","preferredName":"Tumor Proportion Score","longName":"6678073","preferredDefinition":"The percentage of viable tumor cells with partial or complete cell membrane staining.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor Proportion Score","conceptCode":"C154810","definition":"The percentage of viable tumor cells with partial or complete cell membrane staining.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"848AD3E5-3AAA-6CAB-E053-F662850AA7B2","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"848AD3E5-3AC3-6CAB-E053-F662850AA7B2","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","deletedIndicator":"No"},{"value":"STAINING INTENSITY","valueDescription":"Staining Intensity","ValueMeaning":{"publicId":"6678074","version":"1","preferredName":"Staining Intensity","longName":"6678074","preferredDefinition":"The degree or magnitude of staining by a dye or reagent within a microscopic specimen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Staining Intensity","conceptCode":"C127762","definition":"The degree or magnitude of staining by a dye or reagent within a microscopic specimen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"848AD3E5-3ACD-6CAB-E053-F662850AA7B2","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"848AD3E5-3AE6-6CAB-E053-F662850AA7B2","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","deletedIndicator":"No"},{"value":"SCHEUER FIBROSIS SCORE","valueDescription":"Scheuer Fibrosis Score","ValueMeaning":{"publicId":"6678076","version":"1","preferredName":"Scheuer Fibrosis Score","longName":"6678076","preferredDefinition":"A scoring system for liver fibrosis developed by Scheuer (Scheuer PJ. Classification of viral hepatitis: a need for reassessment. J Hepatol 1991;13:372-374), based on a 5 category scale.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Scheuer Fibrosis Score","conceptCode":"C119573","definition":"A scoring system for liver fibrosis developed by Scheuer (Scheuer PJ. Classification of viral hepatitis: a need for reassessment. J Hepatol 1991;13:372-374), based on a 5 category scale.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"848AD3E5-3AF3-6CAB-E053-F662850AA7B2","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"848AD3E5-3B0C-6CAB-E053-F662850AA7B2","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","deletedIndicator":"No"},{"value":"RECEPTOR OVERALL STATUS","valueDescription":"Receptor Overall Status","ValueMeaning":{"publicId":"6678078","version":"1","preferredName":"Receptor Overall Status","longName":"6678078","preferredDefinition":"A qualitative assessment of the status of a biological specimen with regards to a cellular receptor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Receptor Overall Status","conceptCode":"C125989","definition":"A qualitative assessment of the status of a biological specimen with regards to a cellular receptor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"848AD3E5-3B19-6CAB-E053-F662850AA7B2","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"848AD3E5-3B32-6CAB-E053-F662850AA7B2","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","deletedIndicator":"No"},{"value":"AJCC TUMOR GRADE","valueDescription":"AJCC Tumor Grade","ValueMeaning":{"publicId":"6678063","version":"1","preferredName":"AJCC Tumor Grade","longName":"6678063","preferredDefinition":"An assessment of the cellular differentiation of a tumor as per the American Joint Committee on Cancer (AJCC) tumor grading scale.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AJCC Tumor Grade","conceptCode":"C135461","definition":"An assessment of the cellular differentiation of a tumor as per the American Joint Committee on Cancer (AJCC) tumor grading scale.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"848A8DEA-85F9-71B9-E053-F662850A808B","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"848A8DEA-8612-71B9-E053-F662850A808B","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","deletedIndicator":"No"},{"value":"PERCENT POSITIVE CELL","valueDescription":"Percent of Positive Cells","ValueMeaning":{"publicId":"5338013","version":"1","preferredName":"Percent of Positive Cells","longName":"5338013","preferredDefinition":"A quantitative measurement of the proportion of cells that are positive for a given biomarker.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Percent of Positive Cells","conceptCode":"C70460","definition":"A quantitative measurement of the proportion of cells that are positive for a given biomarker.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"370F840B-29A9-B1F0-E050-BB89AD430B36","latestVersionIndicator":"Yes","beginDate":"2016-07-07","endDate":null,"createdBy":"DWARZEL","dateCreated":"2016-07-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"848AD3E5-3B46-6CAB-E053-F662850AA7B2","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","deletedIndicator":"No"},{"value":"METAVIR FIBROSIS SCORE","valueDescription":"METAVIR Fibrosis Score","ValueMeaning":{"publicId":"6678080","version":"1","preferredName":"METAVIR Fibrosis Score","longName":"6678080","preferredDefinition":"A scoring system for liver fibrosis developed by Bedossa and Poynard (Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996 Aug; 24(2):289-93.), based on a 5 category scale.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"METAVIR Fibrosis Score","conceptCode":"C119572","definition":"A scoring system for liver fibrosis developed by Bedossa and Poynard (Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996 Aug; 24(2):289-93.), based on a 5 category scale.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"848AD3E5-3B54-6CAB-E053-F662850AA7B2","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"848AD3E5-3B6D-6CAB-E053-F662850AA7B2","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","deletedIndicator":"No"},{"value":"KNODELL FIBROSIS SCORE","valueDescription":"Knodell Fibrosis Score","ValueMeaning":{"publicId":"6678082","version":"1","preferredName":"Knodell Fibrosis Score","longName":"6678082","preferredDefinition":"A scoring system for liver fibrosis developed by Knodell et al (Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431), based on a 4 category scale.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Knodell Fibrosis Score","conceptCode":"C119571","definition":"A scoring system for liver fibrosis developed by Knodell et al (Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431), based on a 4 category scale.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"848AD3E5-3B7A-6CAB-E053-F662850AA7B2","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"848AD3E5-3B93-6CAB-E053-F662850AA7B2","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","deletedIndicator":"No"},{"value":"ISUP GLEASON GRADE GROUP","valueDescription":"International Society of Urological Pathology Gleason Grade Group","ValueMeaning":{"publicId":"6678084","version":"1","preferredName":"International Society of Urological Pathology Gleason Grade Group","longName":"6678084","preferredDefinition":"A grading system for prostatic adenocarcinoma based on modified Gleason cellular differentiation patterns and Gleason primary and secondary scores (Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA; Grading Committee. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016 Feb;40(2):244-52.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"International Society of Urological Pathology Gleason Grade Group","conceptCode":"C142346","definition":"A grading system for prostatic adenocarcinoma based on modified Gleason cellular differentiation patterns and Gleason primary and secondary scores (Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA; Grading Committee. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016 Feb;40(2):244-52.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"848AD3E5-3BA0-6CAB-E053-F662850AA7B2","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"848AD3E5-3BB9-6CAB-E053-F662850AA7B2","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","deletedIndicator":"No"},{"value":"ISHAK FIBROSIS SCORE","valueDescription":"Ishak Score","ValueMeaning":{"publicId":"6678085","version":"1","preferredName":"Ishak Score","longName":"6678085","preferredDefinition":"A scoring system described by Dr. Ishak and colleagues that assesses the histopathologic degree of liver damage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ishak Score","conceptCode":"C95149","definition":"A scoring system described by Dr. Ishak and colleagues that assesses the histopathologic degree of liver damage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"848AD3E5-3BC3-6CAB-E053-F662850AA7B2","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"848AD3E5-3BDC-6CAB-E053-F662850AA7B2","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","deletedIndicator":"No"},{"value":"H SCORE TOTAL SCORE","valueDescription":"H Score Total Score","ValueMeaning":{"publicId":"6678087","version":"1","preferredName":"H Score Total Score","longName":"6678087","preferredDefinition":"The histopathological evaluation of staining in tissue based on the H Score scoring system (McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716-721).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"H Score Total Score","conceptCode":"C125988","definition":"The histopathological evaluation of staining in tissue based on the H Score scoring system (McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716-721).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"848AD3E5-3BE9-6CAB-E053-F662850AA7B2","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"848AD3E5-3C02-6CAB-E053-F662850AA7B2","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","deletedIndicator":"No"},{"value":"GLEASON TOTAL SUM","valueDescription":"Total Gleason Score For Prostate Cancer","ValueMeaning":{"publicId":"6678088","version":"1","preferredName":"Total Gleason Score For Prostate Cancer","longName":"6678088","preferredDefinition":"The value of the sum of the primary and secondary Gleason scores (range 2-10). If three patterns are identified, it is the sum of the primary pattern score and the score of the least well-differentiated pattern.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Total Gleason Score for Prostate Cancer","conceptCode":"C48602","definition":"The value of the sum of the primary and secondary Gleason scores (range 2-10). If three patterns are identified, it is the sum of the primary pattern score and the score of the least well-differentiated pattern.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"848AD3E5-3C0C-6CAB-E053-F662850AA7B2","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"848AD3E5-3C25-6CAB-E053-F662850AA7B2","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","deletedIndicator":"No"},{"value":"GLEASON SECONDARY SCORE","valueDescription":"Secondary Gleason Pattern","ValueMeaning":{"publicId":"6678089","version":"1","preferredName":"Secondary Gleason Pattern","longName":"6678089","preferredDefinition":"The second most prevalent Gleason pattern in a prostate biopsy or prostatectomy specimen. The Gleason score is defined by adding the most prevalent (primary) and second most prevalent (secondary) patterns.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Secondary Gleason Pattern","conceptCode":"C48604","definition":"The second most prevalent Gleason pattern in a prostate biopsy or prostatectomy specimen. The Gleason score is defined by adding the most prevalent (primary) and second most prevalent (secondary) patterns.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"848AD3E5-3C2F-6CAB-E053-F662850AA7B2","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"848AD3E5-3C48-6CAB-E053-F662850AA7B2","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","deletedIndicator":"No"},{"value":"GLEASON PRIMARY SCORE","valueDescription":"Primary Gleason Pattern","ValueMeaning":{"publicId":"6678090","version":"1","preferredName":"Primary Gleason Pattern","longName":"6678090","preferredDefinition":"The most prevalent Gleason pattern in a prostate biopsy or prostatectomy specimen. The Gleason score is defined by adding the most prevalent (primary) and second most prevalent (secondary) patterns.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Gleason Pattern","conceptCode":"C48603","definition":"The most prevalent Gleason pattern in a prostate biopsy or prostatectomy specimen. The Gleason score is defined by adding the most prevalent (primary) and second most prevalent (secondary) patterns.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"848AD3E5-3C52-6CAB-E053-F662850AA7B2","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"848AD3E5-3C6B-6CAB-E053-F662850AA7B2","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","deletedIndicator":"No"},{"value":"EUROPEAN CONSENSUS SCORE","valueDescription":"European Consensus Score For Bone Marrow Fibrosis","ValueMeaning":{"publicId":"6678092","version":"1","preferredName":"European Consensus Score For Bone Marrow Fibrosis","longName":"6678092","preferredDefinition":"A score based on the European Consensus scale, a grading system for the qualitative and quantitative evaluation of bone marrow fibrosis with a score ranging from zero (normal bone marrow) to three (coarse bundles of collagen fibrosis, usually associated with significant osteosclerosis). (Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005 Aug;90(8):1128-32.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"European Consensus Score For Bone Marrow Fibrosis","conceptCode":"C154809","definition":"A score based on the European Consensus scale, a grading system for the qualitative and quantitative evaluation of bone marrow fibrosis with a score ranging from zero (normal bone marrow) to three (coarse bundles of collagen fibrosis, usually associated with significant osteosclerosis). (Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005 Aug;90(8):1128-32.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"848AD3E5-3C78-6CAB-E053-F662850AA7B2","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"848AD3E5-3C91-6CAB-E053-F662850AA7B2","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","deletedIndicator":"No"},{"value":"ENHANCED LIVER FIBROSIS SCORE","valueDescription":"Enhanced Liver Fibrosis Score","ValueMeaning":{"publicId":"6678094","version":"1","preferredName":"Enhanced Liver Fibrosis Score","longName":"6678094","preferredDefinition":"A scoring system for liver fibrosis developed by Lichtinghagen et al, based on an algorithm that takes into account tissue inhibitor of metalloproteinases 1 (TIMP-1), amino-terminal propeptide of type III procollagen (PIIINP) and hyaluronic acid (HA) levels. (Lichtinghagen R, Pietsch D, Bantel H, Manns MP, Brand K, Bahr MJ. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. J Hepatol. 2013 Aug;59(2):236-42.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enhanced Liver Fibrosis Score","conceptCode":"C132429","definition":"A scoring system for liver fibrosis developed by Lichtinghagen et al, based on an algorithm that takes into account tissue inhibitor of metalloproteinases 1 (TIMP-1), amino-terminal propeptide of type III procollagen (PIIINP) and hyaluronic acid (HA) levels. (Lichtinghagen R, Pietsch D, Bantel H, Manns MP, Brand K, Bahr MJ. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. J Hepatol. 2013 Aug;59(2):236-42.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"848AD3E5-3C9E-6CAB-E053-F662850AA7B2","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"848AD3E5-3CB7-6CAB-E053-F662850AA7B2","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","deletedIndicator":"No"},{"value":"BAUERMEISTER SCORE","valueDescription":"Bauermeister Score","ValueMeaning":{"publicId":"6678096","version":"1","preferredName":"Bauermeister Score","longName":"6678096","preferredDefinition":"A score based on the Bauermeister scale, a 5-point grading system used to rate the extent of myelofibrosis in potential myeloproliferative neoplasms, based on the amount of reticulin and collagen fibers present in the bone marrow. (Bauermeister DE. Quantitation of bone marrow reticulin-a normal range. Am J Clin Pathol. 1971 Jul;56(1):24-31.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bauermeister Score","conceptCode":"C154808","definition":"A score based on the Bauermeister scale, a 5-point grading system used to rate the extent of myelofibrosis in potential myeloproliferative neoplasms, based on the amount of reticulin and collagen fibers present in the bone marrow. (Bauermeister DE. Quantitation of bone marrow reticulin-a normal range. Am J Clin Pathol. 1971 Jul;56(1):24-31.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"848AD3E5-3CC4-6CAB-E053-F662850AA7B2","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"848AD3E5-3CDD-6CAB-E053-F662850AA7B2","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","deletedIndicator":"No"},{"value":"BATTS-LUDWIG FIBROSIS SCORE","valueDescription":"Batts-Ludwig Fibrosis Score","ValueMeaning":{"publicId":"6678098","version":"1","preferredName":"Batts-Ludwig Fibrosis Score","longName":"6678098","preferredDefinition":"A scoring system for liver fibrosis developed by Batts and Ludwig (Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995;19:1409), based on a four category scale.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Batts-Ludwig Fibrosis Score","conceptCode":"C119570","definition":"A scoring system for liver fibrosis developed by Batts and Ludwig (Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995;19:1409), based on a four category scale.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"848AD3E5-3CEA-6CAB-E053-F662850AA7B2","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"848AD3E5-3D03-6CAB-E053-F662850AA7B2","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","deletedIndicator":"No"},{"value":"BANFF QUANTITATIVE CRITERIA SCORE RENAL","valueDescription":"Banff Renal Quantitative Criteria Score","ValueMeaning":{"publicId":"6678100","version":"1","preferredName":"Banff Renal Quantitative Criteria Score","longName":"6678100","preferredDefinition":"A score originally developed by Solez et al. (1993), and assigned based on the histologic evaluation of kidney allograft biopsies and the Banff Working Classification from the Banff Foundation for Allograft Pathology.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Banff Renal Quantitative Criteria Score","conceptCode":"C135462","definition":"A score originally developed by Solez et al. (1993), and assigned based on the histologic evaluation of kidney allograft biopsies and the Banff Working Classification from the Banff Foundation for Allograft Pathology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"848AD3E5-3D10-6CAB-E053-F662850AA7B2","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"848AD3E5-3D29-6CAB-E053-F662850AA7B2","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","deletedIndicator":"No"},{"value":"ALLRED TOTAL SCORE","valueDescription":"Allred Total Score","ValueMeaning":{"publicId":"6678102","version":"1","preferredName":"Allred Total Score","longName":"6678102","preferredDefinition":"The histopathological evaluation of staining in tissue based on the Allred scoring system (Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998 Feb;11(2):155-68).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Allred Total Score","conceptCode":"C125987","definition":"A score for the semi-quantitative staining of estrogen-positive (ER+) or progesterone-positive (PR+) cells in breast cancer tissue samples. It combines a score of 0 through 5 for percentage of stained cells and a score of 0-3 for the intensity of staining. A score of 0-2 is considered negative and 3-8 qualify as positive.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"848AD3E5-3D36-6CAB-E053-F662850AA7B2","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"848AD3E5-3D4F-6CAB-E053-F662850AA7B2","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","deletedIndicator":"No"},{"value":"ALLRED STAINING INTENSITY SCORE","valueDescription":"Allred Average Staining Intensity Score","ValueMeaning":{"publicId":"6678104","version":"1","preferredName":"Allred Average Staining Intensity Score","longName":"6678104","preferredDefinition":"A score developed by Allred et al. (1998) for the average staining intensity for all stained protein-positive cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Allred Average Staining Intensity Score","conceptCode":"C125986","definition":"A score developed by Allred et al. (1998) for the average staining intensity for all stained protein-positive cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"848AD3E5-3D5C-6CAB-E053-F662850AA7B2","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"848AD3E5-3D75-6CAB-E053-F662850AA7B2","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","deletedIndicator":"No"},{"value":"ALLRED PROPORTION POSITIVE SCORE","valueDescription":"Allred Proportion Positive Score","ValueMeaning":{"publicId":"6678106","version":"1","preferredName":"Allred Proportion Positive Score","longName":"6678106","preferredDefinition":"A score developed by Allred et al. (1998) for the proportion of tumor cells that are positive for a given biomarker. The proportion score is assigned based on the biomarker positivity measurement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Allred Proportion Positive Score","conceptCode":"C125985","definition":"A score developed by Allred et al. (1998) for the proportion of tumor cells that are positive for a given biomarker. The proportion score is assigned based on the biomarker positivity measurement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"848AD3E5-3D82-6CAB-E053-F662850AA7B2","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"848AD3E5-3D9B-6CAB-E053-F662850AA7B2","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","deletedIndicator":"No"},{"value":"CHALKLEY SCORE","valueDescription":"Chalkley Score","ValueMeaning":{"publicId":"6775337","version":"1","preferredName":"Chalkley Score","longName":"6775337","preferredDefinition":"A microscopic measurement of the volumetric or area ratios of components of tissues or organs. (Chalkley HW. Method for the quantitative morphological analysis of tissues. J Natl Cancer Inst; 4: 47-52)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chalkley Score","conceptCode":"C158254","definition":"A microscopic measurement of the volumetric or area ratios of components of tissues or organs. (Chalkley HW. Method for the quantitative morphological analysis of tissues. J Natl Cancer Inst; 4: 47-52)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8AA7BAF1-BD4F-28F7-E053-F662850A7ECD","latestVersionIndicator":"Yes","beginDate":"2019-06-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-06-06","modifiedBy":"ONEDATA","dateModified":"2019-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8AA7BAF1-BD68-28F7-E053-F662850A7ECD","beginDate":"2019-06-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-06-06","modifiedBy":"ONEDATA","dateModified":"2019-06-06","deletedIndicator":"No"},{"value":"METMAB SCORE","valueDescription":"METMAB Score","ValueMeaning":{"publicId":"7463349","version":"1","preferredName":"METMAB Score","longName":"7463349","preferredDefinition":"The histopathological evaluation of MET staining in tissue based on the METMAB scoring system. (Spigel DR, Ervin TJ, Ramlau RA, et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2013;31:4105–14.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"METMAB Score","conceptCode":"C174344","definition":"The histopathological evaluation of MET staining in tissue based on the METMAB scoring system. (Spigel DR, Ervin TJ, Ramlau RA, et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2013;31:4105–14.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B17B6610-0F1B-21D2-E053-4EBD850AE0CD","latestVersionIndicator":"Yes","beginDate":"2020-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-10-12","modifiedBy":"ONEDATA","dateModified":"2020-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B17B6610-0F34-21D2-E053-4EBD850AE0CD","beginDate":"2020-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-10-12","modifiedBy":"ONEDATA","dateModified":"2020-10-12","deletedIndicator":"No"},{"value":"GHAS SCORE","valueDescription":"Global Histologic Disease Activity Score","ValueMeaning":{"publicId":"7639427","version":"1","preferredName":"Global Histologic Disease Activity Score","longName":"7639427","preferredDefinition":"A score originally developed by D'Haens et al. (1998) and assigned based on the histologic evaluation of acute and chronic inflammatory changes, epithelial damage, and the extent of inflammation in Crohn's disease mucosal biopsy specimens, according to the Global Histologic Disease Activity Score. (G R D'Haens, K Geboes, M Peeters, F Baert, F Penninckx, P Rutgeerts. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998 Feb;114(2):262-7).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Global Histologic Disease Activity Score","conceptCode":"C178033","definition":"A score originally developed by D'Haens et al. (1998) and assigned based on the histologic evaluation of acute and chronic inflammatory changes, epithelial damage, and the extent of inflammation in Crohn's disease mucosal biopsy specimens, according to the Global Histologic Disease Activity Score. (G R D'Haens, K Geboes, M Peeters, F Baert, F Penninckx, P Rutgeerts. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998 Feb;114(2):262-7).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C07B8E6F-A35F-54BA-E053-4EBD850A8486","latestVersionIndicator":"Yes","beginDate":"2021-04-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-04-21","modifiedBy":"ONEDATA","dateModified":"2021-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C07B8E6F-A378-54BA-E053-4EBD850A8486","beginDate":"2021-04-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-04-21","modifiedBy":"ONEDATA","dateModified":"2021-04-21","deletedIndicator":"No"},{"value":"POSITIVE CELL COUNT","valueDescription":"Positive Cell Count","ValueMeaning":{"publicId":"6618637","version":"1","preferredName":"Positive Cell Count","longName":"6618637","preferredDefinition":"A measurement of the number of cells that stain positively in a sample.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Positive Cell Count","conceptCode":"C156548","definition":"A measurement of the number of cells that stain positively in a sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"803AE359-496D-1532-E053-F662850AD245","latestVersionIndicator":"Yes","beginDate":"2019-01-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-01-24","modifiedBy":"ONEDATA","dateModified":"2019-01-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C07B8E6F-A38C-54BA-E053-4EBD850A8486","beginDate":"2021-04-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-04-21","modifiedBy":"ONEDATA","dateModified":"2021-04-21","deletedIndicator":"No"},{"value":"RHI SCORE","valueDescription":"Robarts Histopathology Index Score","ValueMeaning":{"publicId":"7639425","version":"1","preferredName":"Robarts Histopathology Index Score","longName":"7639425","preferredDefinition":"A score developed by Mosli et al. (2017) and assigned based on the histologic evaluation of disease activity in ulcerative colitis. (Mahmoud H Mosli, Brian G Feagan, Guangyong Zou, et al. Development and validation of a histological index for UC. Gut. 2017 Jan;66(1):50-58.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Robarts Histopathology Index Score","conceptCode":"C178034","definition":"A score developed by Mosli et al. (2017) and assigned based on the histologic evaluation of disease activity in ulcerative colitis. (Mahmoud H Mosli, Brian G Feagan, Guangyong Zou, et al. Development and validation of a histological index for UC. Gut. 2017 Jan;66(1):50-58.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C07B8E6F-A339-54BA-E053-4EBD850A8486","latestVersionIndicator":"Yes","beginDate":"2021-04-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-04-21","modifiedBy":"ONEDATA","dateModified":"2021-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C07B8E6F-A352-54BA-E053-4EBD850A8486","beginDate":"2021-04-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-04-21","modifiedBy":"ONEDATA","dateModified":"2021-04-21","deletedIndicator":"No"},{"value":"H SCORE STAINING INTENSITY 3+","valueDescription":"H Score Staining Intensity 3+","ValueMeaning":{"publicId":"7797884","version":"1","preferredName":"H Score Staining Intensity 3+","longName":"7797884","preferredDefinition":"A measurement of the amount or proportion of cells that have a staining intensity of 3+, based on the H Score scoring system, in a biological specimen. (McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716-721).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"H Score Staining Intensity 3+","conceptCode":"C181476","definition":"A measurement of the amount or proportion of cells that have a staining intensity of 3+, based on the H Score scoring system, in a biological specimen. (McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716-721).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CE2B13F8-7686-5F17-E053-4EBD850ACF75","latestVersionIndicator":"Yes","beginDate":"2021-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-10-12","modifiedBy":"ONEDATA","dateModified":"2021-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CE2B13F8-769F-5F17-E053-4EBD850ACF75","beginDate":"2021-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-10-12","modifiedBy":"ONEDATA","dateModified":"2021-10-12","deletedIndicator":"No"},{"value":"H SCORE STAINING INTENSITY 1+","valueDescription":"H Score Staining Intensity 1+","ValueMeaning":{"publicId":"7797888","version":"1","preferredName":"H Score Staining Intensity 1+","longName":"7797888","preferredDefinition":"A measurement of the amount or proportion of cells that have a staining intensity of 1+, based on the H Score scoring system, in a biological specimen. (McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716-721).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"H Score Staining Intensity 1+","conceptCode":"C181474","definition":"A measurement of the amount or proportion of cells that have a staining intensity of 1+, based on the H Score scoring system, in a biological specimen. (McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716-721).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CE2B13F8-76D2-5F17-E053-4EBD850ACF75","latestVersionIndicator":"Yes","beginDate":"2021-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-10-12","modifiedBy":"ONEDATA","dateModified":"2021-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CE2B13F8-76EB-5F17-E053-4EBD850ACF75","beginDate":"2021-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-10-12","modifiedBy":"ONEDATA","dateModified":"2021-10-12","deletedIndicator":"No"},{"value":"H SCORE STAINING INTENSITY 2+","valueDescription":"H Score Staining Intensity 2+","ValueMeaning":{"publicId":"7797886","version":"1","preferredName":"H Score Staining Intensity 2+","longName":"7797886","preferredDefinition":"A measurement of the amount or proportion of cells that have a staining intensity of 2+, based on the H Score scoring system, in a biological specimen. (McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716-721).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"H Score Staining Intensity 2+","conceptCode":"C181475","definition":"A measurement of the amount or proportion of cells that have a staining intensity of 2+, based on the H Score scoring system, in a biological specimen. (McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716-721).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CE2B13F8-76AC-5F17-E053-4EBD850ACF75","latestVersionIndicator":"Yes","beginDate":"2021-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-10-12","modifiedBy":"ONEDATA","dateModified":"2021-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CE2B13F8-76C5-5F17-E053-4EBD850ACF75","beginDate":"2021-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-10-12","modifiedBy":"ONEDATA","dateModified":"2021-10-12","deletedIndicator":"No"},{"value":"H SCORE STAINING INTENSITY 0","valueDescription":"H Score Staining Intensity 0","ValueMeaning":{"publicId":"7797890","version":"1","preferredName":"H Score Staining Intensity 0","longName":"7797890","preferredDefinition":"A measurement of the amount or proportion of cells that have a staining intensity of 0, based on the H Score scoring system, in a biological specimen. (McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716-721).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"H Score Staining Intensity 0","conceptCode":"C181473","definition":"A measurement of the amount or proportion of cells that have a staining intensity of 0, based on the H Score scoring system, in a biological specimen. (McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716-721).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CE2B13F8-76F8-5F17-E053-4EBD850ACF75","latestVersionIndicator":"Yes","beginDate":"2021-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-10-12","modifiedBy":"ONEDATA","dateModified":"2021-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CE2B13F8-7711-5F17-E053-4EBD850ACF75","beginDate":"2021-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-10-12","modifiedBy":"ONEDATA","dateModified":"2021-10-12","deletedIndicator":"No"},{"value":"NAFLD ACTIVITY SCORE","valueDescription":"Non-Alcoholic Fatty Liver Disease Activity Score","ValueMeaning":{"publicId":"7797892","version":"1","preferredName":"Non-Alcoholic Fatty Liver Disease Activity Score","longName":"7797892","preferredDefinition":"The histopathological evaluation of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) based on the NAFLD scoring system. (Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005 Jun;41(6):1313-21.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Alcoholic Fatty Liver Disease Activity Score","conceptCode":"C181472","definition":"The histopathological evaluation of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) based on the NAFLD scoring system. (Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005 Jun;41(6):1313-21.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CE2B13F8-771E-5F17-E053-4EBD850ACF75","latestVersionIndicator":"Yes","beginDate":"2021-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-10-12","modifiedBy":"ONEDATA","dateModified":"2021-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CE2B13F8-7737-5F17-E053-4EBD850ACF75","beginDate":"2021-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-10-12","modifiedBy":"ONEDATA","dateModified":"2021-10-12","deletedIndicator":"No"},{"value":"IDWORAK TUMOR REGRESSION GRADE 1997","valueDescription":"iDworak et al Tumor Regression Grade (1997)","ValueMeaning":{"publicId":"7797894","version":"1","preferredName":"iDworak et al Tumor Regression Grade (1997)","longName":"7797894","preferredDefinition":"A grading system developed by Dworak et al (1997) to assess a decrease in tumor size or extent in the body. (Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. (1997) 12:19-23.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"iDworak et al Tumor Regression Grade (1997)","conceptCode":"C181471","definition":"A grading system developed by Dworak et al (1997) to assess a decrease in tumor size or extent in the body. (Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. (1997) 12:19-23.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CE2B13F8-7744-5F17-E053-4EBD850ACF75","latestVersionIndicator":"Yes","beginDate":"2021-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-10-12","modifiedBy":"ONEDATA","dateModified":"2021-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CE2B13F8-775D-5F17-E053-4EBD850ACF75","beginDate":"2021-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-10-12","modifiedBy":"ONEDATA","dateModified":"2021-10-12","deletedIndicator":"No"},{"value":"HARTMAN TUMOR REGRESSION GRADE 2012","valueDescription":"Hartman et al Tumor Regression Grade (2012)","ValueMeaning":{"publicId":"7797896","version":"1","preferredName":"Hartman et al Tumor Regression Grade (2012)","longName":"7797896","preferredDefinition":"A grading system developed by Hartman et al (2012) to assess a decrease in tumor size or extent in the body (Hartman DJ, Krasinskas AM. Assessing treatment effect in pancreatic cancer. Arch Pathol Lab Med. (2012) 136:100-9.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hartman et al Tumor Regression Grade (2012)","conceptCode":"C181470","definition":"A grading system developed by Hartman et al (2012) to assess a decrease in tumor size or extent in the body (Hartman DJ, Krasinskas AM. Assessing treatment effect in pancreatic cancer. Arch Pathol Lab Med. (2012) 136:100-9.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CE2B13F8-776A-5F17-E053-4EBD850ACF75","latestVersionIndicator":"Yes","beginDate":"2021-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-10-12","modifiedBy":"ONEDATA","dateModified":"2021-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CE2B13F8-7783-5F17-E053-4EBD850ACF75","beginDate":"2021-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-10-12","modifiedBy":"ONEDATA","dateModified":"2021-10-12","deletedIndicator":"No"},{"value":"EVANS TUMOR REGRESSION GRADE 1992","valueDescription":"Evans et al Tumor Regression Grade (1992)","ValueMeaning":{"publicId":"7797898","version":"1","preferredName":"Evans et al Tumor Regression Grade (1992)","longName":"7797898","preferredDefinition":"A grading system developed by Evans et al (1992) to assess a decrease in tumor size or extent in the body. (Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. (1992) 127:1335-9.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Evans et al Tumor Regression Grade (1992)","conceptCode":"C181469","definition":"A grading system developed by Evans et al (1992) to assess a decrease in tumor size or extent in the body. (Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. (1992) 127:1335-9.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CE2B13F8-7790-5F17-E053-4EBD850ACF75","latestVersionIndicator":"Yes","beginDate":"2021-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-10-12","modifiedBy":"ONEDATA","dateModified":"2021-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CE2B13F8-77A9-5F17-E053-4EBD850ACF75","beginDate":"2021-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-10-12","modifiedBy":"ONEDATA","dateModified":"2021-10-12","deletedIndicator":"No"},{"value":"MD ANDERSON TUMOR REGRESSION GRADE 2012","valueDescription":"MD Anderson Tumor Regression Grade (2012)","ValueMeaning":{"publicId":"7797900","version":"1","preferredName":"MD Anderson Tumor Regression Grade (2012)","longName":"7797900","preferredDefinition":"A grading system developed by Chatterjee et al (2012) to assess a decrease in tumor size or extent in the body. (Chatterjee D, Katz MH, Rashid A, Wolff RA, Wang H, Lee JE, et al. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. Cancer. (2012) 118:3182-90.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MD Anderson Tumor Regression Grade (2012)","conceptCode":"C181468","definition":"A grading system developed by Chatterjee et al (2012) to assess a decrease in tumor size or extent in the body. (Chatterjee D, Katz MH, Rashid A, Wolff RA, Wang H, Lee JE, et al. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. Cancer. (2012) 118:3182-90.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CE2B13F8-77B6-5F17-E053-4EBD850ACF75","latestVersionIndicator":"Yes","beginDate":"2021-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-10-12","modifiedBy":"ONEDATA","dateModified":"2021-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CE2B13F8-77CF-5F17-E053-4EBD850ACF75","beginDate":"2021-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-10-12","modifiedBy":"ONEDATA","dateModified":"2021-10-12","deletedIndicator":"No"},{"value":"CAP TUMOR REGRESSION GRADE","valueDescription":"College of American Pathology Tumor Regression Grade","ValueMeaning":{"publicId":"7797902","version":"1","preferredName":"College of American Pathology Tumor Regression Grade","longName":"7797902","preferredDefinition":"A grading system developed by the College of American Pathology to assess a decrease in tumor size or extent in the body (Shi C, Adsay V, Bergsland E, Berlin J, Branton P, Fitzgibbons P, et al. College of American pathologist, protocol for the examination of specimens from patients with carcinoma of the pancreas. Version: PancreasExocrine 4.0.0.1. (2017).)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"College of American Pathology Tumor Regression Grade","conceptCode":"C181467","definition":"A grading system developed by the College of American Pathology to assess a decrease in tumor size or extent in the body (Shi C, Adsay V, Bergsland E, Berlin J, Branton P, Fitzgibbons P, et al. College of American pathologist, protocol for the examination of specimens from patients with carcinoma of the pancreas. Version: PancreasExocrine 4.0.0.1. (2017).)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CE2B13F8-77DC-5F17-E053-4EBD850ACF75","latestVersionIndicator":"Yes","beginDate":"2021-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-10-12","modifiedBy":"ONEDATA","dateModified":"2021-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CE2B13F8-77F5-5F17-E053-4EBD850ACF75","beginDate":"2021-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-10-12","modifiedBy":"ONEDATA","dateModified":"2021-10-12","deletedIndicator":"No"},{"value":"NOTTINGHAM HISTOLOGIC GRADE","valueDescription":"Nottingham Grade","ValueMeaning":{"publicId":"7797903","version":"1","preferredName":"Nottingham Grade","longName":"7797903","preferredDefinition":"A grade assigned to invasive breast carcinoma samples that is based on the sum of the Nottigham scores for glandular (acinar)/tubular differentiation, nuclear pleomorphism, and mitotic rate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nottingham Grade","conceptCode":"C138986","definition":"A histologic grading system developed by Elston and Ellis as a modification of the Scarff-Bloom-Richardson grading system, based on tubule formation, nuclear pleomorphism, and mitotic counts of invasive adenocarcinomas. (CW Ellston, O Ellis. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991 Nov;19(5):403-10.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CE2B13F8-7801-5F17-E053-4EBD850ACF75","latestVersionIndicator":"Yes","beginDate":"2021-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-10-12","modifiedBy":"ONEDATA","dateModified":"2021-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CE2B13F8-781A-5F17-E053-4EBD850ACF75","beginDate":"2021-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-10-12","modifiedBy":"ONEDATA","dateModified":"2021-10-12","deletedIndicator":"No"},{"value":"STAINING INTENSITY 3+","valueDescription":"Staining Intensity 3+","ValueMeaning":{"publicId":"8158287","version":"1","preferredName":"Staining Intensity 3+","longName":"8158287","preferredDefinition":"A measurement of the amount or proportion of tissue or cells that have a staining intensity of 3+.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Staining Intensity 3+","conceptCode":"C186202","definition":"A measurement of the amount or proportion of tissue or cells that have a staining intensity of 3+.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC893C73-EAE7-0C82-E053-4EBD850A8E62","latestVersionIndicator":"Yes","beginDate":"2022-04-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-04-13","modifiedBy":"ONEDATA","dateModified":"2022-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DC893C73-EB00-0C82-E053-4EBD850A8E62","beginDate":"2022-04-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-04-13","modifiedBy":"ONEDATA","dateModified":"2022-04-13","deletedIndicator":"No"},{"value":"STAINING INTENSITY 2+","valueDescription":"Staining Intensity 2+","ValueMeaning":{"publicId":"8158289","version":"1","preferredName":"Staining Intensity 2+","longName":"8158289","preferredDefinition":"A measurement of the amount or proportion of tissue or cells that have a staining intensity of 2+.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Staining Intensity 2+","conceptCode":"C186201","definition":"A measurement of the amount or proportion of tissue or cells that have a staining intensity of 2+.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC893C73-EB0D-0C82-E053-4EBD850A8E62","latestVersionIndicator":"Yes","beginDate":"2022-04-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-04-13","modifiedBy":"ONEDATA","dateModified":"2022-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DC893C73-EB26-0C82-E053-4EBD850A8E62","beginDate":"2022-04-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-04-13","modifiedBy":"ONEDATA","dateModified":"2022-04-13","deletedIndicator":"No"},{"value":"STAINING INTENSITY 1+","valueDescription":"Staining Intensity 1+","ValueMeaning":{"publicId":"8158291","version":"1","preferredName":"Staining Intensity 1+","longName":"8158291","preferredDefinition":"A measurement of the amount or proportion of tissue or cells that have a staining intensity of 1+.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Staining Intensity 1+","conceptCode":"C186200","definition":"A measurement of the amount or proportion of tissue or cells that have a staining intensity of 1+.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC893C73-EB33-0C82-E053-4EBD850A8E62","latestVersionIndicator":"Yes","beginDate":"2022-04-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-04-13","modifiedBy":"ONEDATA","dateModified":"2022-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DC893C73-EB4C-0C82-E053-4EBD850A8E62","beginDate":"2022-04-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-04-13","modifiedBy":"ONEDATA","dateModified":"2022-04-13","deletedIndicator":"No"},{"value":"STAINING INTENSITY 0","valueDescription":"Staining Intensity 0","ValueMeaning":{"publicId":"8158293","version":"1","preferredName":"Staining Intensity 0","longName":"8158293","preferredDefinition":"A measurement of the amount or proportion of tissue or cells that have a staining intensity of 0.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Staining Intensity 0","conceptCode":"C186199","definition":"A measurement of the amount or proportion of tissue or cells that have a staining intensity of 0.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC893C73-EB59-0C82-E053-4EBD850A8E62","latestVersionIndicator":"Yes","beginDate":"2022-04-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-04-13","modifiedBy":"ONEDATA","dateModified":"2022-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DC893C73-EB72-0C82-E053-4EBD850A8E62","beginDate":"2022-04-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-04-13","modifiedBy":"ONEDATA","dateModified":"2022-04-13","deletedIndicator":"No"},{"value":"FIGO TUMOR GRADE","valueDescription":null,"ValueMeaning":{"publicId":"11009261","version":"1","preferredName":"FIGO Tumor Grade","longName":"11009261v1.00","preferredDefinition":"A tumor histopathologic grading system developed by Bhatla et al (2018) for uterine and cervical cancers. (Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaecol Obstet 2018;143(Suppl 2):22-36.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FIGO Tumor Grade","conceptCode":"C187943","definition":"A tumor histopathologic grading system developed by Bhatla et al (2018) for uterine and cervical cancers. (Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaecol Obstet 2018;143(Suppl 2):22-36.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5BBE286-221F-69B7-E053-731AD00AFFB1","latestVersionIndicator":"Yes","beginDate":"2022-08-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-08","modifiedBy":"KUMMEROA","dateModified":"2022-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E5BBE286-2222-69B7-E053-731AD00AFFB1","beginDate":"2022-08-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-08","modifiedBy":"KUMMEROA","dateModified":"2022-08-08","deletedIndicator":"No"},{"value":"JASS RECTAL CANCER PROGNOSTIC CLASSIFICATION 1987","valueDescription":null,"ValueMeaning":{"publicId":"11009262","version":"1","preferredName":"JASS Rectal Cancer Prognostic Classification 1987","longName":"11009262v1.00","preferredDefinition":"A classification system for rectal cancer prognosis based on four histomorphologic parameters. (JR Jass, SB Love, JM Northover. A new prognostic classification of rectal cancer. Lancet 1987 Jun 6;1(8545):1303-6.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"JASS Rectal Cancer Prognostic Classification 1987","conceptCode":"C187944","definition":"A classification system for rectal cancer prognosis based on four histomorphologic parameters. (JR Jass, SB Love, JM Northover. A new prognostic classification of rectal cancer. Lancet 1987 Jun 6;1(8545):1303-6.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5BBE286-2220-69B7-E053-731AD00AFFB1","latestVersionIndicator":"Yes","beginDate":"2022-08-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-08","modifiedBy":"KUMMEROA","dateModified":"2022-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E5BBE286-2223-69B7-E053-731AD00AFFB1","beginDate":"2022-08-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-08","modifiedBy":"KUMMEROA","dateModified":"2022-08-08","deletedIndicator":"No"},{"value":"WHO/ISUP NUCLEAR GRADE","valueDescription":null,"ValueMeaning":{"publicId":"11009263","version":"1","preferredName":"WHO/ISUP Fuhrman Nuclear Grade","longName":"11009263v1.00","preferredDefinition":"A tumor grading system developed by the members of the ISUP Renal Tumor Panel (2013) that evaluates nuclear grade in renal cell carcinomas. (Delahunt B., Cheville J.C., Martignoni G., Humphrey P.A., Magi-Galluzzi C., McKenney J., Egevad L., Algaba F., Moch H., Grignon D.J., Montironi R., Srigley J.R., Members of the ISUP Renal Tumor Panel. International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013;37:1490-1504.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"WHO/ISUP Fuhrman Nuclear Grade","conceptCode":"C187945","definition":"A tumor grading system developed by the members of the ISUP Renal Tumor Panel (2013) that evaluates nuclear grade in renal cell carcinomas. (Delahunt B., Cheville J.C., Martignoni G., Humphrey P.A., Magi-Galluzzi C., McKenney J., Egevad L., Algaba F., Moch H., Grignon D.J., Montironi R., Srigley J.R., Members of the ISUP Renal Tumor Panel. International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013;37:1490-1504.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5BBE286-2221-69B7-E053-731AD00AFFB1","latestVersionIndicator":"Yes","beginDate":"2022-08-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-08","modifiedBy":"KUMMEROA","dateModified":"2022-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E5BBE286-2224-69B7-E053-731AD00AFFB1","beginDate":"2022-08-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-08","modifiedBy":"KUMMEROA","dateModified":"2022-08-08","deletedIndicator":"No"},{"value":"FUHRMAN NUCLEAR GRADE","valueDescription":null,"ValueMeaning":{"publicId":"2794437","version":"1","preferredName":"Fuhrman Nuclear Grade","longName":"2794437","preferredDefinition":"A 4-point scale that indicates the level of protein synthesis activity in malignant cells based on the appearance of the nuclei. The grading ranges from I (best prognosis) to IV (worst prognosis).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fuhrman Nuclear Grade","conceptCode":"C62411","definition":"A 4-point scale for renal cell carcinoma that indicates the level of protein synthesis activity in malignant cells based on the appearance of the nuclei. The grading ranges from I (best prognosis) to IV (worst prognosis).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"59EC1A6B-90DD-012F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"LEEB","dateCreated":"2008-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E5BBE286-2225-69B7-E053-731AD00AFFB1","beginDate":"2022-08-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-08","modifiedBy":"KUMMEROA","dateModified":"2022-08-08","deletedIndicator":"No"},{"value":"WHO CLASSIFICATION OF TUMORS OF THE DIGESTIVE SYSTEM 2010","valueDescription":null,"ValueMeaning":{"publicId":"11483266","version":"1","preferredName":"WHO Classification of Tumors of the Digestive System 2010","longName":"11483266v1.00","preferredDefinition":"A classification for grading and staging of tumors of the digestive system published by the World Health Organization (WHO) in 2010. (Bosman F, Carneiro F: World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Digestive System., Lyon: IARC Press, 2010.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"WHO Classification of Tumors of the Digestive System 2010","conceptCode":"C189616","definition":"A classification for grading and staging of tumors of the digestive system published by the World Health Organization (WHO) in 2010. (Bosman F, Carneiro F: World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Digestive System., Lyon: IARC Press, 2010.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EBCD9CED-0ADE-3480-E053-731AD00AF8D1","latestVersionIndicator":"Yes","beginDate":"2022-10-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-24","modifiedBy":"KUMMEROA","dateModified":"2022-10-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EBCD9CED-0AE2-3480-E053-731AD00AF8D1","beginDate":"2022-10-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-24","modifiedBy":"KUMMEROA","dateModified":"2022-10-24","deletedIndicator":"No"},{"value":"WHO CLASSIFICATION OF TUMORS OF ENDOCRINE ORGANS 2017","valueDescription":null,"ValueMeaning":{"publicId":"11483267","version":"1","preferredName":"WHO Classification of Tumors of Endocrine Organs 2017","longName":"11483267v1.00","preferredDefinition":"A classification for grading and staging of tumors of endocrine organs published by the World Health Organization (WHO) in 2017. (Lloyd RV, Osamura R, Kloppel G, Rosai J. WHO Classification of Tumours of Endocrine Organs. 4th ed. Lyon: IARC Press; 2017.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"WHO Classification of Tumors of Endocrine Organs 2017","conceptCode":"C189617","definition":"A classification for grading and staging of tumors of endocrine organs published by the World Health Organization (WHO) in 2017. (Lloyd RV, Osamura R, Kloppel G, Rosai J. WHO Classification of Tumours of Endocrine Organs. 4th ed. Lyon: IARC Press; 2017.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EBCD9CED-0ADF-3480-E053-731AD00AF8D1","latestVersionIndicator":"Yes","beginDate":"2022-10-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-24","modifiedBy":"KUMMEROA","dateModified":"2022-10-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EBCD9CED-0AE3-3480-E053-731AD00AF8D1","beginDate":"2022-10-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-24","modifiedBy":"KUMMEROA","dateModified":"2022-10-24","deletedIndicator":"No"},{"value":"WHO CLASSIFICATION OF TUMORS OF THE DIGESTIVE SYSTEM 2019","valueDescription":null,"ValueMeaning":{"publicId":"11483268","version":"1","preferredName":"WHO Classification of Tumors of the Digestive System 2019","longName":"11483268v1.00","preferredDefinition":"A classification for grading and staging of tumors of the digestive system published by the World Health Organization (WHO) in 2019. (Iris D Nagtegaal, Robert D Odze, David Klimstra, Valerie Paradis, Massimo Rugge, Peter Schirmacher, Kay M Washington, Fatima Carneiro, Ian A Cree, and the WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020 Jan; 76(2): 182-188.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"WHO Classification of Tumors of the Digestive System 2019","conceptCode":"C189618","definition":"A classification for grading and staging of tumors of the digestive system published by the World Health Organization (WHO) in 2019. (Iris D Nagtegaal, Robert D Odze, David Klimstra, Valerie Paradis, Massimo Rugge, Peter Schirmacher, Kay M Washington, Fatima Carneiro, Ian A Cree, and the WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020 Jan; 76(2): 182-188.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EBCD9CED-0AE0-3480-E053-731AD00AF8D1","latestVersionIndicator":"Yes","beginDate":"2022-10-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-24","modifiedBy":"KUMMEROA","dateModified":"2022-10-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EBCD9CED-0AE4-3480-E053-731AD00AF8D1","beginDate":"2022-10-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-24","modifiedBy":"KUMMEROA","dateModified":"2022-10-24","deletedIndicator":"No"},{"value":"IARC AND WHO CLASSIFICATION OF NEUROENDOCRINE NEOPLASMS 2018","valueDescription":null,"ValueMeaning":{"publicId":"11483269","version":"1","preferredName":"IARC and WHO Classification of Tumors of Neuroendocrine Neoplasms 2018","longName":"11483269v1.00","preferredDefinition":"A classification for grading and staging of neuroendocrine neoplasms published by the World Health Organization (WHO) in 2018. (Rindi, G., Klimstra, D.S., Abedi-Ardekani, B. et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 31, 1770-1786 (2018).)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IARC and WHO Classification of Tumors of Neuroendocrine Neoplasms 2018","conceptCode":"C189619","definition":"A classification for grading and staging of neuroendocrine neoplasms published by the World Health Organization (WHO) in 2018. (Rindi, G., Klimstra, D.S., Abedi-Ardekani, B. et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 31, 1770-1786 (2018).)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EBCD9CED-0AE1-3480-E053-731AD00AF8D1","latestVersionIndicator":"Yes","beginDate":"2022-10-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-24","modifiedBy":"KUMMEROA","dateModified":"2022-10-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EBCD9CED-0AE5-3480-E053-731AD00AF8D1","beginDate":"2022-10-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-24","modifiedBy":"KUMMEROA","dateModified":"2022-10-24","deletedIndicator":"No"},{"value":"PROLIFERATIVE INDEX","valueDescription":null,"ValueMeaning":{"publicId":"13361713","version":"1","preferredName":"Proliferative Index","longName":"13361713v1.00","preferredDefinition":"The percentage of cells in a biological specimen that are dividing.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Proliferative Index","conceptCode":"C28042","definition":"The percentage of cells in a biological specimen that are dividing.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F94E647E-C178-0599-E053-731AD00A7F7B","latestVersionIndicator":"Yes","beginDate":"2023-04-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-14","modifiedBy":"KUMMEROA","dateModified":"2023-04-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F94E647E-C179-0599-E053-731AD00A7F7B","beginDate":"2023-04-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-14","modifiedBy":"KUMMEROA","dateModified":"2023-04-14","deletedIndicator":"No"},{"value":"EPSTEIN PROSTATE NEC CLASSIFICATION 2014","valueDescription":null,"ValueMeaning":{"publicId":"14091737","version":"1","preferredName":"Epstein Prostate Neuroendocrine Carcinoma Classification 2014","longName":"14091737v1.00","preferredDefinition":"A morphologic classification system for prostate carcinoma with neuroendocrine differentiation by Epstein et al (2014). (Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera JM, Reuter VE, Robinson BD, Troncoso P, Rubin MA. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014 Jun;38(6):756-67.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epstein Prostate Neuroendocrine Carcinoma Classification 2014","conceptCode":"C199977","definition":"A morphologic classification system for prostate carcinoma with neuroendocrine differentiation by Epstein et al (2014). (Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera JM, Reuter VE, Robinson BD, Troncoso P, Rubin MA. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014 Jun;38(6):756-67.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"00C3A8BB-DD32-6E66-E063-731AD00A6C5B","latestVersionIndicator":"Yes","beginDate":"2023-07-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-07-18","modifiedBy":"KUMMEROA","dateModified":"2023-07-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"00C3A8BB-DDEA-6E66-E063-731AD00A6C5B","beginDate":"2023-07-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-07-18","modifiedBy":"KUMMEROA","dateModified":"2023-07-18","deletedIndicator":"No"},{"value":"UNSPECIFIED TUMOR GRADE CLASSIFICATION","valueDescription":null,"ValueMeaning":{"publicId":"14091738","version":"1","preferredName":"Unspecified Tumor Grade Classification","longName":"14091738v1.00","preferredDefinition":"The tumor grade classification system used in the assessment was not stated explicitly or in detail.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unspecified Tumor Grade Classification","conceptCode":"C199978","definition":"The tumor grade classification system used in the assessment was not stated explicitly or in detail.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"00C3A8BB-DD33-6E66-E063-731AD00A6C5B","latestVersionIndicator":"Yes","beginDate":"2023-07-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-07-18","modifiedBy":"KUMMEROA","dateModified":"2023-07-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"00C3A8BB-DDEB-6E66-E063-731AD00A6C5B","beginDate":"2023-07-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-07-18","modifiedBy":"KUMMEROA","dateModified":"2023-07-18","deletedIndicator":"No"},{"value":"WHO CLASSIFICATION OF TUMORS OF HEMATOPOIETIC AND LYMPHOID TISSUE 2017","valueDescription":null,"ValueMeaning":{"publicId":"14091739","version":"1","preferredName":"WHO Classification of Tumors of Hematopoietic And Lymphoid Tissue 2017","longName":"14091739v1.00","preferredDefinition":"A classification for grading and staging of tumors of hematopoietic and lymphoid tissue published by the World Health Organization (WHO) in 2017. (WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO Classification of Tumours, Revised 4th Edition, Volume 2. Edited by Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. 2017)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"WHO Classification of Tumors of Hematopoietic And Lymphoid Tissue 2017","conceptCode":"C199979","definition":"A classification for grading and staging of tumors of hematopoietic and lymphoid tissue published by the World Health Organization (WHO) in 2017. (WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO Classification of Tumours, Revised 4th Edition, Volume 2. Edited by Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. 2017)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"00C3A8BB-DD34-6E66-E063-731AD00A6C5B","latestVersionIndicator":"Yes","beginDate":"2023-07-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-07-18","modifiedBy":"KUMMEROA","dateModified":"2023-07-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"00C3A8BB-DDEC-6E66-E063-731AD00A6C5B","beginDate":"2023-07-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-07-18","modifiedBy":"KUMMEROA","dateModified":"2023-07-18","deletedIndicator":"No"},{"value":"ALLRED TOTAL SCORE INTERPRETATION","valueDescription":null,"ValueMeaning":{"publicId":"14091740","version":"1","preferredName":"Allred Total Score Interpretation","longName":"14091740v1.00","preferredDefinition":"The interpretation of the findings of the Allred Total Score, the histopathological evaluation of staining in tissue based on the Allred scoring system. Scores of 0-2 are considered negative expression and scores of 3-8 are considered positive expression. (Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998 Feb;11(2):155-68).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Allred Total Score Interpretation","conceptCode":"C199980","definition":"The interpretation of the findings of the Allred Total Score, the histopathological evaluation of staining in tissue based on the Allred scoring system. Scores of 0-2 are considered negative expression and scores of 3-8 are considered positive expression. (Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998 Feb;11(2):155-68).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"00C3A8BB-DD35-6E66-E063-731AD00A6C5B","latestVersionIndicator":"Yes","beginDate":"2023-07-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-07-18","modifiedBy":"KUMMEROA","dateModified":"2023-07-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"00C3A8BB-DDED-6E66-E063-731AD00A6C5B","beginDate":"2023-07-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-07-18","modifiedBy":"KUMMEROA","dateModified":"2023-07-18","deletedIndicator":"No"},{"value":"FAB CLASSIFICATION 1985","valueDescription":null,"ValueMeaning":{"publicId":"14091741","version":"1","preferredName":"FAB Classification 1985","longName":"14091741v1.00","preferredDefinition":"A classification for grading and staging of acute leukemias published by the French-American-British (FAB) co-operative group in 1985. (Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103(4):620-625.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FAB Classification 1985","conceptCode":"C199981","definition":"A classification for grading and staging of acute leukemias published by the French-American-British (FAB) co-operative group in 1985. (Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103(4):620-625.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"00C3A8BB-DD36-6E66-E063-731AD00A6C5B","latestVersionIndicator":"Yes","beginDate":"2023-07-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-07-18","modifiedBy":"KUMMEROA","dateModified":"2023-07-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"00C3A8BB-DDEE-6E66-E063-731AD00A6C5B","beginDate":"2023-07-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-07-18","modifiedBy":"KUMMEROA","dateModified":"2023-07-18","deletedIndicator":"No"},{"value":"BRESLOW DEPTH","valueDescription":null,"ValueMeaning":{"publicId":"14091742","version":"1","preferredName":"Breslow Thickness","longName":"14091742v1.00","preferredDefinition":"The measurement in millimeters of the vertical thickness of primary cutaneous melanoma.  Breslow thickness is measured from the granular layer of the epidermis, or the ulcer base (if ulcerated), to the deepest tumor cells.  It is used in staging of melanoma. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breslow Thickness","conceptCode":"C25734","definition":"The measurement in millimeters of the vertical thickness of primary cutaneous melanoma.  Breslow thickness is measured from the granular layer of the epidermis, or the ulcer base (if ulcerated), to the deepest tumor cells.  It is used in staging of melanoma. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"00C3A8BB-DD37-6E66-E063-731AD00A6C5B","latestVersionIndicator":"Yes","beginDate":"2023-07-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-07-18","modifiedBy":"KUMMEROA","dateModified":"2023-07-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"00C3A8BB-DDEF-6E66-E063-731AD00A6C5B","beginDate":"2023-07-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-07-18","modifiedBy":"KUMMEROA","dateModified":"2023-07-18","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435019","version":"1","preferredName":"Conceptual Entity","preferredDefinition":"An organizational header for concepts representing mostly abstract entities.","longName":"C20181","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D8-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6678060","version":"1","preferredName":"CDISC SDTM Microscopic Findings Test Detail Terminology Type","preferredDefinition":"Terminology associated with the microscopic findings test detail codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).:Something distinguishable as an identifiable class based on common qualities.","longName":"C125922:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CDISC SDTM Microscopic Findings Test Detail Terminology","conceptCode":"C125922","definition":"Terminology associated with the microscopic findings test detail codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"848A8DEA-85D0-71B9-E053-F662850A808B","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CDISC:Clinical Data Interchange Standards Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"848A8DEA-85E1-71B9-E053-F662850A808B","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"KUMMEROA","dateModified":"2023-07-18","changeDescription":"2022-4-13 ak Updated to CT Package 49 release. 2021-10-12 ak Updated to CT Package 47 release. 2021-6-10 ak Released per governance approval.  2021-4-16 ak Updated to CT Package 45 release. 2020-10-12 ak Updated to CT Package 43 release. 3-20-19 Curated to support CDISC Initiative; tmt. 6.6.19 Added PVs for CT package 37 release. mc","administrativeNotes":"2023.4.14 Updated to CT Package 53 release. ak 2022.8.8 Updated to CT Package 50 release.  ak  2022.10.24 Updated to CT Package 51 release.  ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6338162","version":"1","longName":"CDISC (NCI Implementation)","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"6338163","version":"1","longName":"CDASH","context":"NCI Standards"},{"publicId":"7329805","version":"1","longName":"Optional Core","context":"NCI Standards"},{"publicId":"7329804","version":"1","longName":"Microscopic Findings (MI) Domain","context":"NCI Standards"},{"publicId":"7218795","version":"1","longName":"SDTM","context":"NCI Standards"},{"publicId":"10000098","version":"1","longName":"Microscopic Findings (MI) Domain","context":"NCI Standards"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Case Report Form","type":"CDISC CRF Instruction","description":"Record the detail of the microscopic examination, if not pre-printed on the CRF.","url":null,"context":"NCI Standards"},{"name":"MITSTDTL","type":"CDASH to SDTM Mapping","description":"Maps directly to the SDTMIG variable.","url":null,"context":"NCI Standards"},{"name":"CDASH Implementation Notes","type":"CDASH Implementation Note","description":"Provide additional details for the microscopic examination. It is recommended that the test detail be pre-printed on the CRF. If the form is laid out as a grid, then words such as Test Detail can be included as the column header.","url":null,"context":"NCI Standards"},{"name":"What was the microscopic exam","type":"Preferred Question Text","description":"What was the microscopic examination detail?","url":null,"context":"NCI Standards"},{"name":"CDASH PROMPT","type":"Alternate Question Text","description":"[Examination Name Detail]","url":null,"context":"NCI Standards"},{"name":"CDISC SDTM Microscopic Findings Test Detail Terminology","type":"VALID_VALUE_SOURCE","description":"Terminology associated with the microscopic findings test detail codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","url":"https://ncit.nci.nih.gov/ncitbrowser/ajax?action=create_src_vs_tree&amp;vsd_uri=http%3A//evs.nci.nih.gov/valueset/CDISC/C125922","context":"NCI Standards"}],"origin":"CDISC:Clinical Data Interchange Standards Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"746E5639-2315-6FEF-E053-F662850A6A05","latestVersionIndicator":"Yes","beginDate":"2018-08-27","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-08-27","modifiedBy":"KUMMEROA","dateModified":"2021-06-10","changeDescription":"2021-6-10 ak Released per governance approval.  3/20/19 VD changed from 6338238 to 6678061/SDTM 3.3; tmt. Created as part of the CDISC mapping task_ghd_08.27.18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}